Comparing the efficacy of antioxidants riboflavin (B2) and zinc (Zn) On the symptoms of peripheral vertigo

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240317061318N1

Enrollment

146

Registered

2024-12-15

Start date

2023-09-23

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Vertigo. Other peripheral vertigo

Interventions

Intervention 1: Intervention group: Patients receiving zinc. Intervention 2: Intervention group: Patients receiving b2.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patient consent Age between 18 and 65 years Visit for the first time with a complaint of peripheral vertigo Absence of contraindications for the administration of zinc or riboflavin

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Peripheral vertigo score in VAS (Visual Analogue Scale). Timepoint: The beginning of the study and 30 days after the start of consumption. Method of measurement: phone call with the patients.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactOmid Ehsani

Bandare-abbas University of Medical Sciences

Omid.omid.ehsani3@gmail.com+98 76 3258 0335

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026